慢性淋巴细胞白血病中TP53、BIRC3、ATM和MAPK-ERK基因的临床意义:来自英国LRF CLL4随机试验的数据
该研究对499例LRF CLL4试验病例进行22基因靶向重测序,鉴定出623个突变。≥12% VAF的TP53突变与无进展生存期和总生存期缩短相关,双等位BIRC3病变是 inferior PFS和OS的独立标志物,MAPK-ERK基因突变是poor OS的独立标志物。
要点
- ≥12% VAF的TP53突变与PFS和OS缩短相关,<12% VAF TP53突变与野生型或≥12% VAF组无差异。
- 双等位BIRC3病变(突变和缺失)是PFS和OS不良的独立标志物。
- MAPK-ERK基因突变是多变量生存分析中OS不良的独立标志物。
核心结论
- 靶向重测序扩展基因面板有助于阐明基因突变对CLL的预后影响。
研究设计与样本
- 研究纳入499例LRF CLL4试验病例,随访超过12年,对22个基因进行靶向重测序。
主要发现
- 共鉴定出623个突变;经背景突变率校正后,22个基因中有11个反复突变,频率从3.6%(NFKBIE)到24%(SF3B1)。
- 所有基因均观察到低于Sanger分辨率的突变(<12% VAF),KRAS突变主要由这些低VAF变异组成。
- ≥12% VAF的TP53突变病例与PFS和OS降低相关,<12% VAF TP53突变与野生型或≥12% VAF TP53突变病例之间未显示差异。
- 双等位BIRC3病变(突变和缺失)是PFS和OS不良的独立标志物。
- MAPK-ERK基因突变是多变量生存分析中OS不良的独立标志物。
关键数值与推荐
- 反复突变频率范围为3.6%(NFKBIE)至24%(SF3B1)。
- TP53突变以12% VAF为界,≥12% VAF与PFS和OS降低相关。
临床怎么用
- 考虑使用扩展基因面板的靶向重测序来评估CLL患者的基因突变预后。
- 关注TP53突变克隆架构(VAF≥12%)、双等位BIRC3病变和MAPK-ERK基因突变以进行风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite advances in chronic lymphocytic leukaemia (CLL) treatment, globally chemotherapy remains a central treatment modality, with chemotherapy trials representing an invaluable resource to explore disease-related/genetic features contributing to long-term outcomes. In 499 LRF CLL4 cases, a trial with >12 years follow-up, we employed targeted resequencing of 22 genes, identifying 623 mutations. After background mutation rate correction, 11/22 genes were recurrently mutated at frequencies between 3.6% (NFKBIE) and 24% (SF3B1). Mutations beyond Sanger resolution (<12% VAF) were observed in all genes, with KRAS mutations principally composed of these low VAF variants. Firstly, employing orthogonal approaches to confirm <12% VAF TP53 mutations, we assessed the clinical impact of TP53 clonal architecture. Whilst ≥ 12% VAF TP53mut cases were associated with reduced PFS and OS, we could not demonstrate a difference between <12% VAF TP53 mutations and either wild type or ≥12% VAF TP53mut cases. Secondly, we identified biallelic BIRC3 lesions (mutation and deletion) as an independent marker of inferior PFS and OS. Finally, we observed that mutated MAPK-ERK genes were independent markers of poor OS in multivariate survival analysis. In conclusion, our study supports using targeted resequencing of expanded gene panels to elucidate the prognostic impact of gene mutations.
引用
- Blakemore SJ, Clifford R, Parker H, et al. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial. Leukemia. 2020. PMID: 32015491. doi:10.1038/s41375-020-0723-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。